Alu and LINE-1 Hypomethylation is Associated with HER2 Enriched Subtype of Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jun 28

PMID 24971511

Citations 38

Authors

So Yeon Park

An Na Seo

Hae Yoen Jung

Jae Moon Gwak

Namhee Jung

Nam-Yun Cho

Gyeong Hoon Kang

Affiliations

Soon will be listed here.

Abstract

The changes in DNA methylation status in cancer cells are characterized by hypermethylation of promoter CpG islands and diffuse genomic hypomethylation. Alu and long interspersed nucleotide element-1 (LINE-1) are non-coding genomic repetitive sequences and methylation of these elements can be used as a surrogate marker for genome-wide methylation status. This study was designed to evaluate the changes of Alu and LINE-1 hypomethylation during breast cancer progression from normal to pre-invasive lesions and invasive breast cancer (IBC), and their relationship with characteristics of IBC. We analyzed the methylation status of Alu and LINE-1 in 145 cases of breast samples including normal breast tissue, atypical ductal hyperplasia/flat epithelial atypia (ADH/FEA), ductal carcinoma in situ (DCIS) and IBC, and another set of 129 cases of IBC by pyrosequencing. Alu methylation showed no significant changes during multistep progression of breast cancer, although it tended to decrease during the transition from DCIS to IBC. In contrast, LINE-1 methylation significantly decreased from normal to ADH/FEA, while it was similar in ADH/FEA, DCIS and IBC. In IBC, Alu hypomethylation correlated with negative estrogen receptor (ER) status, and LINE-1 hypomethylation was associated with negative ER status, ERBB2 (HER2) amplification and p53 overexpression. Alu and LINE-1 methylation status was significantly different between breast cancer subtypes, and the HER2 enriched subtype had lowest methylation levels. In survival analyses, low Alu methylation status tended to be associated with poor disease-free survival of the patients. Our findings suggest that LINE-1 hypomethylation is an early event and Alu hypomethylation is probably a late event during breast cancer progression, and prominent hypomethylation of Alu and LINE-1 in HER2 enriched subtype may be related to chromosomal instability of this specific subtype.

Citing Articles

The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment.

Kim D Curr Oncol. 2025; 32(2).

PMID: 39996888 PMC: 11854558. DOI: 10.3390/curroncol32020088.

LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers.

Gezer U, Ozgur E, Yoruker E, Polatoglou E, Holdenrieder S, Bronkhorst A Cancers (Basel). 2024; 16(22).

PMID: 39594682 PMC: 11592170. DOI: 10.3390/cancers16223725.

Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects.

Mustafin R Explor Target Antitumor Ther. 2024; 5(5):1011-1026.

PMID: 39351441 PMC: 11438560. DOI: 10.37349/etat.2024.00261.

Alterations of senescence-associated markers in patients with non-syndromic cleft lip and palate.

Charoenvicha C, Thongsroy J, Apaijai N, Attachaipanich T, Sirimaharaj W, Khwanngern K Sci Rep. 2024; 14(1):22555.

PMID: 39343816 PMC: 11439953. DOI: 10.1038/s41598-024-74353-0.

Alu RNA fold links splicing with signal recognition particle proteins.

Borovska I, Vorechovsky I, Kralovicova J Nucleic Acids Res. 2023; 51(15):8199-8216.

PMID: 37309897 PMC: 10450188. DOI: 10.1093/nar/gkad500.

References

Yoder J, Walsh C, Bestor T . Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997; 13(8):335-40. DOI: 10.1016/s0168-9525(97)01181-5. View

Goel A, Xicola R, Nguyen T, Doyle B, Sohn V, Bandipalliam P . Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology. 2010; 138(5):1854-62. PMC: 2859993. DOI: 10.1053/j.gastro.2010.01.035. View

Costello J, Fruhwald M, Smiraglia D, Rush L, Robertson G, Gao X . Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24(2):132-8. DOI: 10.1038/72785. View

Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T . Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst. 2012; 105(2):130-40. PMC: 3545905. DOI: 10.1093/jnci/djs482. View

Lee H, Kim B, Cho N, Yoo E, Choi M, Shin S . Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):812-20. DOI: 10.1158/1078-0432.CCR-08-0266. View

van Hoesel A, van de Velde C, Kuppen P, Liefers G, Putter H, Sato Y . Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat. 2012; 134(3):1103-14. DOI: 10.1007/s10549-012-2038-0. View

Voduc K, Cheang M, Tyldesley S, Gelmon K, Nielsen T, Kennecke H . Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10):1684-91. DOI: 10.1200/JCO.2009.24.9284. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Bae J, Shin S, Kwon H, Park S, Kook M, Kim Y . ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications. Int J Cancer. 2011; 131(6):1323-31. DOI: 10.1002/ijc.27369. View

10.

Ogino S, Nosho K, Kirkner G, Kawasaki T, Chan A, Schernhammer E . A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008; 100(23):1734-8. PMC: 2639290. DOI: 10.1093/jnci/djn359. View

11.

Kitkumthorn N, Mutirangura A . Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenetics. 2012; 2(2):315-30. PMC: 3365388. DOI: 10.1007/s13148-011-0032-8. View

12.

Kamalakaran S, Varadan V, Giercksky Russnes H, Levy D, Kendall J, Janevski A . DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol. 2010; 5(1):77-92. PMC: 5528275. DOI: 10.1016/j.molonc.2010.11.002. View

13.

Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung B . Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res. 2000; 5(12):4140-5. View

14.

Ikeda K, Shiraishi K, Eguchi A, Shibata H, Yoshimoto K, Mori T . Long interspersed nucleotide element 1 hypomethylation is associated with poor prognosis of lung adenocarcinoma. Ann Thorac Surg. 2013; 96(5):1790-4. DOI: 10.1016/j.athoracsur.2013.06.035. View

15.

Delgado-Cruzata L, Wu H, Liao Y, Santella R, Terry M . Differences in DNA methylation by extent of breast cancer family history in unaffected women. Epigenetics. 2013; 9(2):243-8. PMC: 3962534. DOI: 10.4161/epi.26880. View

16.

Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T . Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res. 2010; 16(8):2418-26. DOI: 10.1158/1078-0432.CCR-09-2819. View

17.

Ellsworth R, Ellsworth D, Patney H, Deyarmin B, Love B, Hooke J . Amplification of HER2 is a marker for global genomic instability. BMC Cancer. 2008; 8:297. PMC: 2571108. DOI: 10.1186/1471-2407-8-297. View

18.

Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird P . Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 2006; 66(1):29-33. DOI: 10.1158/0008-5472.CAN-05-2508. View

19.

Lengauer C, Kinzler K, Vogelstein B . DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A. 1997; 94(6):2545-50. PMC: 20125. DOI: 10.1073/pnas.94.6.2545. View

20.

Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H . Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010; 12(3):R36. PMC: 2917031. DOI: 10.1186/bcr2590. View